Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alamar Biosciences, Inc.ALMR · Entity 1791 | Director | September 01, 2026 | September 03, 2026 |
| GRAIL, Inc.GRAL · Entity 4122 | Director · Chief Executive Officer | April 08, 2026 | April 09, 2026 |
| ILLUMINA, INC.ILMN · Entity 3137 | SVP, Global Quality & Ops | February 17, 2021 | February 18, 2021 |
| Twist Bioscience CorpTWST · Entity 3619 | Director | February 05, 2026 | February 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alamar Biosciences, Inc.
Report date September 01, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,686 |
Reported balance
After 2026-09-01 transaction · row 1
1 source rowRow 1 · 2026-09-01 · Grant · Acquired 5,686 · Balance 5,686 F1: Represents a restricted stock unit ("RSU") award. The RSUs vest in equal annual installments over 3 years measured from September 1, 2026, subject to the reporting person's continuous service as of each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.36 · Expires 2036-08-31 | Direct | 25,599 |
Reported balance
After 2026-09-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-01 · Grant · Acquired 25,599 · Balance 25,599 F2: One-third of the shares subject to the option will vest on September 1, 2027 and the remainder of the shares subject to the grant will vest in equal monthly installments thereafter through September 1, 2029, subject to the reporting person's continuous service as of each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted stock unit ("RSU") award. The RSUs vest in equal annual installments over 3 years measured from September 1, 2026, subject to the reporting person's continuous service as of each such vesting date.
F2: One-third of the shares subject to the option will vest on September 1, 2027 and the remainder of the shares subject to the grant will vest in equal monthly installments thereafter through September 1, 2029, subject to the reporting person's continuous service as of each such vesting date.
GRAIL, Inc.
Report date April 08, 2026 · Filed April 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 518,582 |
Reported balance
After 2026-04-08 transaction · row 1
1 source rowRow 1 · 2026-04-08 · Sale · Disposed 123,502 · Balance 518,582 F1: Represents automatic 'sell-to-cover' transactions by an executing broker to cover withholding taxes upon award vesting and share delivery. The price reported in Column 4 is a weighted average price calculated by the broker executing these transactions. These shares were sold as part of a block trade in multiple transactions, and the Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate sales price. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents automatic 'sell-to-cover' transactions by an executing broker to cover withholding taxes upon award vesting and share delivery. The price reported in Column 4 is a weighted average price calculated by the broker executing these transactions. These shares were sold as part of a block trade in multiple transactions, and the Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate sales price.
ILLUMINA, INC.
Report date February 17, 2021 · Filed February 18, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,617 |
Ending reported balance
After 2021-02-17 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2021-02-17 · Grant · Acquired 694 · Balance 6,489 F1: Represents additional shares of stock awarded as a result of the Company achieving at least 111% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on December 11, 2017. Row 2 · 2021-02-17 · Exercise / conversion · Acquired 6,306 · Balance 12,795 F2: Represents shares of stock awarded as a result of the Company achieving at least 100% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on December 11, 2017. Row 3 · 2021-02-17 · Tax withholding · Disposed 3,178 · Balance 9,617 |
| Performance SharesSEC Table II · derivative / convertible security · Expires 2021-01-03 | Direct | 0 |
Reported balance
After 2021-02-17 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-02-17 · Exercise / conversion · Disposed 6,306 · Balance 0 F2: Represents shares of stock awarded as a result of the Company achieving at least 100% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on December 11, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents additional shares of stock awarded as a result of the Company achieving at least 111% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on December 11, 2017.
F2: Represents shares of stock awarded as a result of the Company achieving at least 100% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on December 11, 2017.
Twist Bioscience Corp
Report date February 05, 2026 · Filed February 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 28,983 |
Reported balance
After 2026-02-05 transaction · row 1
1 source rowRow 1 · 2026-02-05 · Grant · Acquired 5,095 · Balance 28,983 F1: 100% of the Shares subject to the Annual Equity Award will vest upon the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the first annual meeting of stockholders following the date of grant, provided that the Non-Employee Director is a Service Provider on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the Shares subject to the Annual Equity Award will vest upon the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the first annual meeting of stockholders following the date of grant, provided that the Non-Employee Director is a Service Provider on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 31, 2020 Filed Sep 2, 2020 23:29 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 850 | $356.00 | $302,597.79 |
DisclosureSEC source: 0001127602-20-024654 · form4.xml · nonDerivative · entry 4 RAGUSA ROBERT P · CIK 0001222644 · SVP, Global Quality & Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,736 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F6 · price: Weighted average sale price representing 850 shares sold ranging from $355.77 to $356.55 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Canc Read SEC document |
| August 31, 2020 Filed Sep 2, 2020 23:29 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 1,852 | $355.31 | $658,025.05 |
DisclosureSEC source: 0001127602-20-024654 · form4.xml · nonDerivative · entry 3 RAGUSA ROBERT P · CIK 0001222644 · SVP, Global Quality & Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,586 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F5 · price: Weighted average sale price representing 1,852 shares sold ranging from $354.75 to $355.75 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Canc Read SEC document |
| August 31, 2020 Filed Sep 2, 2020 23:29 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 1,100 | $354.09 | $389,497.46 |
DisclosureSEC source: 0001127602-20-024654 · form4.xml · nonDerivative · entry 2 RAGUSA ROBERT P · CIK 0001222644 · SVP, Global Quality & Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,438 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F4 · price: Weighted average sale price representing 1,100 shares sold ranging from $353.74 to $354.54 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Canc Read SEC document |
| August 31, 2020 Filed Sep 2, 2020 23:29 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 565 | $352.93 | $199,403.92 |
DisclosureSEC source: 0001127602-20-024654 · form4.xml · nonDerivative · entry 1 RAGUSA ROBERT P · CIK 0001222644 · SVP, Global Quality & Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,538 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F3 · price: Weighted average sale price representing 565 shares sold ranging from $352.73 to $353.555 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Canc F2 · balance_after: Balance includes 47 shares acquired through Employee Stock Purchase Plan. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 20:15 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 300 | $344.04 | $103,212.00 |
DisclosureSEC source: 0001127602-20-019906 · form4.xml · nonDerivative · entry 8 RAGUSA ROBERT P · CIK 0001222644 · SVP, Global Quality & Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,056 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F9 · price: Weighted average sale price representing 300 shares sold ranging from $343.74 to $344.41 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 20:15 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 663 | $343.18 | $227,528.34 |
DisclosureSEC source: 0001127602-20-019906 · form4.xml · nonDerivative · entry 7 RAGUSA ROBERT P · CIK 0001222644 · SVP, Global Quality & Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,356 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F8 · price: Weighted average sale price representing 663 shares sold ranging from $342.69 to $343.69 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 20:15 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 1,155 | $341.98 | $394,986.90 |
DisclosureSEC source: 0001127602-20-019906 · form4.xml · nonDerivative · entry 6 RAGUSA ROBERT P · CIK 0001222644 · SVP, Global Quality & Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,019 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F7 · price: Weighted average sale price representing 1,155 shares sold ranging from $341.61 to $342.60 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 20:15 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 896 | $341.23 | $305,742.08 |
DisclosureSEC source: 0001127602-20-019906 · form4.xml · nonDerivative · entry 5 RAGUSA ROBERT P · CIK 0001222644 · SVP, Global Quality & Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,174 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F6 · price: Weighted average sale price representing 896 shares sold ranging from $340.56 to $341.56 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 20:15 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 500 | $338.74 | $169,370.00 |
DisclosureSEC source: 0001127602-20-019906 · form4.xml · nonDerivative · entry 4 RAGUSA ROBERT P · CIK 0001222644 · SVP, Global Quality & Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,070 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F5 · price: Weighted average sale price representing 500 shares sold ranging from $338.49 to $338.99 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 20:15 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 450 | $338.06 | $152,127.00 |
DisclosureSEC source: 0001127602-20-019906 · form4.xml · nonDerivative · entry 3 RAGUSA ROBERT P · CIK 0001222644 · SVP, Global Quality & Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,570 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F4 · price: Weighted average sale price representing 450 shares sold ranging from $337.46 to $338.42 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 20:15 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 461 | $336.97 | $155,343.17 |
DisclosureSEC source: 0001127602-20-019906 · form4.xml · nonDerivative · entry 2 RAGUSA ROBERT P · CIK 0001222644 · SVP, Global Quality & Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,595 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F3 · price: Weighted average sale price representing 461 shares sold ranging from $336.40 to $337.31 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 20:15 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 575 | $340.00 | $195,500.00 |
DisclosureSEC source: 0001127602-20-019906 · form4.xml · nonDerivative · entry 1 RAGUSA ROBERT P · CIK 0001222644 · SVP, Global Quality & Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,020 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F2 · price: Weighted average sale price representing 575 shares sold ranging from $339.50 to $340.46 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document |
| February 11, 2020 Filed Feb 14, 2020 01:06 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Exercise / conversionPerformance Shares · Derivative | 9,969 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005387 · form4.xml · derivative · entry 4 RAGUSA ROBERT P · CIK 0001222644 · SVP, Global Quality & Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,969 shares Expires 2019-12-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Represents shares of stock awarded as a result of the Company achieving at least 100% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on December 2, 2016. F2 · shares: Represents shares of stock awarded as a result of the Company achieving at least 100% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on December 2, 2016. F2 · derivative.exercise_date: Represents shares of stock awarded as a result of the Company achieving at least 100% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on December 2, 2016. Read SEC document |
| February 11, 2020 Filed Feb 14, 2020 01:06 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Tax withholdingCommon Stock | 6,920 | $296.00 | $2,048,320.00 |
DisclosureSEC source: 0001127602-20-005387 · form4.xml · nonDerivative · entry 3 RAGUSA ROBERT P · CIK 0001222644 · SVP, Global Quality & Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,056 Read SEC document |
| February 11, 2020 Filed Feb 14, 2020 01:06 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Exercise / conversionCommon Stock | 9,969 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005387 · form4.xml · nonDerivative · entry 2 RAGUSA ROBERT P · CIK 0001222644 · SVP, Global Quality & Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,976 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Represents shares of stock awarded as a result of the Company achieving at least 100% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on December 2, 2016. Read SEC document |
| February 11, 2020 Filed Feb 14, 2020 01:06 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantCommon Stock | 4,985 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005387 · form4.xml · nonDerivative · entry 1 RAGUSA ROBERT P · CIK 0001222644 · SVP, Global Quality & Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,007 F1 · shares: Represents additional shares of stock awarded as a result of the Company achieving at least 150% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on December 2, 2016. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 23:00 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantPerformance Shares · Derivative | 6,243 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-004410 · form4.xml · derivative · entry 2 RAGUSA ROBERT P · CIK 0001222644 · SVP, Global Quality & Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,243 Underlying: Common Stock · 6,243 shares Expires 2023-01-01 F3 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending January 1, 2023. The number of shares issued will range from 0% to 150% of the amount specified above, based on the company's actual earnings per share for the fiscal year ending January 1, 2023, relative to pre-defined objectives, subject to awardee's continuing status as a service provider on such dates. F3 · derivative.exercise_date: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending January 1, 2023. The number of shares issued will range from 0% to 150% of the amount specified above, based on the company's actual earnings per share for the fiscal year ending January 1, 2023, relative to pre-defined objectives, subject to awardee's continuing status as a service provider on such dates. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 23:00 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantCommon Stock | 2,081 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-004410 · form4.xml · nonDerivative · entry 1 RAGUSA ROBERT P · CIK 0001222644 · SVP, Global Quality & Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,022 F1 · shares: Grant of restricted stock units shall vest as follows: 25% of the shares subject to the award shall vest on each of February 5, 2021, February 5, 2022, February 5, 2023 and February 5, 2024, subject to awardee's continuing status as a service provider on such dates. F2 · balance_after: Balance includes 53 shares acquired through Employee Stock Purchase Plan. Read SEC document |
| February 04, 2020 Filed Feb 7, 2020 02:26 UTC | Twist Bioscience Corp TWST · Entity 3619 | GrantDirector Stock Option (right to buy) · Derivative | 5,648 | $0.00 Strike: $26.20 | $0.00 |
DisclosureSEC source: 0001214659-20-001016 · marketforms-47703.xml · derivative · entry 3 RAGUSA ROBERT P · CIK 0001222644 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,648 Underlying: Common Stock · 5,648 shares Expires 2030-02-03 F3 · derivative.exercise_date: 100% of the shares subject to the option will vest and become exercisable on the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Issuer's first annual meeting of stockholders following the date of grant, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| February 04, 2020 Filed Feb 7, 2020 02:26 UTC | Twist Bioscience Corp TWST · Entity 3619 | GrantCommon Stock | 1,412 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-20-001016 · marketforms-47703.xml · nonDerivative · entry 1 RAGUSA ROBERT P · CIK 0001222644 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,412 F1 · shares: Represents a restricted stock unit award (the "RSU Award") of which 100% vests on the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Issuer's first annual meeting of stockholders following the date of grant, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| February 04, 2020 Filed Mar 5, 2021 21:40 UTC Amendment | Twist Bioscience Corp TWST · Entity 3619 | GrantDirector Stock Option (right to buy) · Derivative | 11,297 | $0.00 Strike: $26.20 | $0.00 |
DisclosureSEC source: 0001214659-21-002798 · marketforms-51441.xml · derivative · entry 1 RAGUSA ROBERT P · CIK 0001222644 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,297 Underlying: Common Stock · 11,297 shares Expires 2030-02-03 F1 · shares: The Form 4 originally filed on February 6,2020 incorrectly reported 5,648 options. F2 · derivative.exercise_date: 100% of the shares subject to the option will vest and become exercisable on the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Issuer's first annual meeting of stockholders following the date of grant, subject to the Reporting Person's continuous service through each vesting date. F1 · derivative.underlying_shares: The Form 4 originally filed on February 6,2020 incorrectly reported 5,648 options. F1 · balance_after: The Form 4 originally filed on February 6,2020 incorrectly reported 5,648 options. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 22:37 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 1,253 | $293.10 | $367,254.30 |
DisclosureSEC source: 0001127602-20-003811 · form4.xml · nonDerivative · entry 1 RAGUSA ROBERT P · CIK 0001222644 · SVP, Global Quality & Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,888 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| November 05, 2019 Filed Nov 7, 2019 21:42 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Tax withholdingCommon Stock | 1,051 | $300.87 | $316,214.37 |
DisclosureSEC source: 0001127602-19-032201 · form4.xml · nonDerivative · entry 1 RAGUSA ROBERT P · CIK 0001222644 · SVP, Global Quality & Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,141 Read SEC document |
| November 01, 2019 Filed Nov 5, 2019 21:18 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 1,674 | $297.28 | $497,646.72 |
DisclosureSEC source: 0001127602-19-031882 · form4.xml · nonDerivative · entry 1 RAGUSA ROBERT P · CIK 0001222644 · SVP, Global Quality & Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,192 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| August 08, 2019 Filed Aug 12, 2019 21:22 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 2,230 | $293.09 | $653,590.70 |
DisclosureSEC source: 0001127602-19-026433 · form4.xml · nonDerivative · entry 1 RAGUSA ROBERT P · CIK 0001222644 · SVP, Global Quality & Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,866 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F2 · balance_after: Balance includes 48 shares acquired through Employee Stock Purchase Plan. Read SEC document |
| July 23, 2019 Filed Oct 9, 2019 20:34 UTC | Twist Bioscience Corp TWST · Entity 3619 | GrantDirector Stock Option (right to buy) · Derivative | 5,590 | $0.00 Strike: $30.41 | $0.00 |
DisclosureSEC source: 0001209191-19-052822 · doc4.xml · derivative · entry 1 RAGUSA ROBERT P · CIK 0001222644 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,590 Underlying: Common Stock · 5,590 shares Expires 2029-07-22 F1 · derivative.exercise_date: 100% of the shares subject to the option will vest and become exercisable on the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Issuer's first annual meeting of stockholders following the date of grant, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| July 23, 2019 Filed Mar 5, 2021 21:30 UTC Amendment | Twist Bioscience Corp TWST · Entity 3619 | GrantDirector Stock Option (right to buy) · Derivative | 10,588 | $0.00 Strike: $30.41 | $0.00 |
DisclosureSEC source: 0001214659-21-002785 · marketforms-51615.xml · derivative · entry 1 RAGUSA ROBERT P · CIK 0001222644 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,588 Underlying: Common Stock · 10,588 shares Expires 2029-07-22 F1 · shares: The Form 4 originally filed on October 9,2019 incorrectly reported 5,590 options. F2 · derivative.exercise_date: 100% of the shares subject to the option will vest and become exercisable on the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Issuer's first annual meeting of stockholders following the date of grant, subject to the Reporting Person's continuous service through each vesting date. F1 · derivative.underlying_shares: The Form 4 originally filed on October 9,2019 incorrectly reported 5,590 options. F1 · balance_after: The Form 4 originally filed on October 9,2019 incorrectly reported 5,590 options. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 21:32 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Exercise / conversionPerformance Shares · Derivative | 4,540 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-006007 · form4.xml · derivative · entry 4 RAGUSA ROBERT P · CIK 0001222644 · SVP, Global Quality & Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,540 shares Expires 2018-12-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares of stock awarded as a result of the Company achieving at least 100% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on December 8, 2015. F1 · shares: Represents shares of stock awarded as a result of the Company achieving at least 100% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on December 8, 2015. F1 · derivative.exercise_date: Represents shares of stock awarded as a result of the Company achieving at least 100% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on December 8, 2015. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 21:32 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Tax withholdingCommon Stock | 2,222 | $292.20 | $649,268.40 |
DisclosureSEC source: 0001127602-19-006007 · form4.xml · nonDerivative · entry 3 RAGUSA ROBERT P · CIK 0001222644 · SVP, Global Quality & Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,048 F3 · balance_after: Balance includes 58 shares acquired through Employee Stock Purchase Plan. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 21:32 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantCommon Stock | 954 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-006007 · form4.xml · nonDerivative · entry 2 RAGUSA ROBERT P · CIK 0001222644 · SVP, Global Quality & Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,270 F2 · shares: Represents additional shares of stock awarded as a result of the Company achieving at least 121% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on December 8, 2015. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 21:32 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Exercise / conversionCommon Stock | 4,540 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-006007 · form4.xml · nonDerivative · entry 1 RAGUSA ROBERT P · CIK 0001222644 · SVP, Global Quality & Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,316 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of stock awarded as a result of the Company achieving at least 100% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on December 8, 2015. Read SEC document |
| November 02, 2018 Filed Nov 6, 2018 22:01 UTC | Twist Bioscience Corp TWST · Entity 3619 | ConversionSeries D Preferred Stock · Derivative | 157,215 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-057432 · doc4.xml · derivative · entry 9 RAGUSA ROBERT P · CIK 0001222644 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Illumina, Inc. Disclosed balance after: 0 Underlying: Common Stock · 157,215 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock have no expiration date and converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: The Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock have no expiration date and converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: The Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock have no expiration date and converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering. F2 · ownership.nature: The Reporting Person is the Senior Vice President, Global Quality and Operations of Illumina, Inc. and has sole voting and dispositive power over the shares held of record by Illumina, Inc. The Reporting Person disclaims beneficial ownership in these shares except as to the Reporting Person's pecuniary interest therein. Read SEC document |
| November 02, 2018 Filed Nov 6, 2018 22:01 UTC | Twist Bioscience Corp TWST · Entity 3619 | ConversionSeries C Preferred Stock · Derivative | 673,378 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-057432 · doc4.xml · derivative · entry 8 RAGUSA ROBERT P · CIK 0001222644 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Illumina, Inc. Disclosed balance after: 0 Underlying: Common Stock · 673,378 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock have no expiration date and converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: The Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock have no expiration date and converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: The Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock have no expiration date and converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering. F2 · ownership.nature: The Reporting Person is the Senior Vice President, Global Quality and Operations of Illumina, Inc. and has sole voting and dispositive power over the shares held of record by Illumina, Inc. The Reporting Person disclaims beneficial ownership in these shares except as to the Reporting Person's pecuniary interest therein. Read SEC document |
| November 02, 2018 Filed Nov 6, 2018 22:01 UTC | Twist Bioscience Corp TWST · Entity 3619 | ConversionSeries B Preferred Stock · Derivative | 329,305 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-057432 · doc4.xml · derivative · entry 7 RAGUSA ROBERT P · CIK 0001222644 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Illumina, Inc. Disclosed balance after: 0 Underlying: Common Stock · 329,305 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock have no expiration date and converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: The Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock have no expiration date and converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: The Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock have no expiration date and converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering. F2 · ownership.nature: The Reporting Person is the Senior Vice President, Global Quality and Operations of Illumina, Inc. and has sole voting and dispositive power over the shares held of record by Illumina, Inc. The Reporting Person disclaims beneficial ownership in these shares except as to the Reporting Person's pecuniary interest therein. Read SEC document |
| November 02, 2018 Filed Nov 6, 2018 22:01 UTC | Twist Bioscience Corp TWST · Entity 3619 | ConversionSeries A Preferred Stock · Derivative | 542,203 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-057432 · doc4.xml · derivative · entry 6 RAGUSA ROBERT P · CIK 0001222644 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Illumina, Inc. Disclosed balance after: 0 Underlying: Common Stock · 542,203 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock have no expiration date and converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: The Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock have no expiration date and converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: The Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock have no expiration date and converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering. F2 · ownership.nature: The Reporting Person is the Senior Vice President, Global Quality and Operations of Illumina, Inc. and has sole voting and dispositive power over the shares held of record by Illumina, Inc. The Reporting Person disclaims beneficial ownership in these shares except as to the Reporting Person's pecuniary interest therein. Read SEC document |
| November 02, 2018 Filed Nov 6, 2018 22:01 UTC | Twist Bioscience Corp TWST · Entity 3619 | ConversionCommon Stock | 157,215 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-057432 · doc4.xml · nonDerivative · entry 4 RAGUSA ROBERT P · CIK 0001222644 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Illumina, Inc. Disclosed balance after: 1,702,101 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock have no expiration date and converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering. F2 · ownership.nature: The Reporting Person is the Senior Vice President, Global Quality and Operations of Illumina, Inc. and has sole voting and dispositive power over the shares held of record by Illumina, Inc. The Reporting Person disclaims beneficial ownership in these shares except as to the Reporting Person's pecuniary interest therein. Read SEC document |
| November 02, 2018 Filed Nov 6, 2018 22:01 UTC | Twist Bioscience Corp TWST · Entity 3619 | ConversionCommon Stock | 673,378 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-057432 · doc4.xml · nonDerivative · entry 3 RAGUSA ROBERT P · CIK 0001222644 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Illumina, Inc. Disclosed balance after: 1,544,886 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock have no expiration date and converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering. F2 · ownership.nature: The Reporting Person is the Senior Vice President, Global Quality and Operations of Illumina, Inc. and has sole voting and dispositive power over the shares held of record by Illumina, Inc. The Reporting Person disclaims beneficial ownership in these shares except as to the Reporting Person's pecuniary interest therein. Read SEC document |
| November 02, 2018 Filed Nov 6, 2018 22:01 UTC | Twist Bioscience Corp TWST · Entity 3619 | ConversionCommon Stock | 329,305 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-057432 · doc4.xml · nonDerivative · entry 2 RAGUSA ROBERT P · CIK 0001222644 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Illumina, Inc. Disclosed balance after: 871,508 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock have no expiration date and converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering. F2 · ownership.nature: The Reporting Person is the Senior Vice President, Global Quality and Operations of Illumina, Inc. and has sole voting and dispositive power over the shares held of record by Illumina, Inc. The Reporting Person disclaims beneficial ownership in these shares except as to the Reporting Person's pecuniary interest therein. Read SEC document |
| November 02, 2018 Filed Nov 6, 2018 22:01 UTC | Twist Bioscience Corp TWST · Entity 3619 | ConversionCommon Stock | 542,203 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-057432 · doc4.xml · nonDerivative · entry 1 RAGUSA ROBERT P · CIK 0001222644 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Illumina, Inc. Disclosed balance after: 542,203 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock have no expiration date and converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering. F2 · ownership.nature: The Reporting Person is the Senior Vice President, Global Quality and Operations of Illumina, Inc. and has sole voting and dispositive power over the shares held of record by Illumina, Inc. The Reporting Person disclaims beneficial ownership in these shares except as to the Reporting Person's pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.